CSTL: TissueCypher and melanoma test growth, AI integration, and regulatory advances drive expansion
Strong growth in molecular diagnostics, especially for TissueCypher, is supported by expanding sales teams and AI-driven technology. Regulatory progress and new evidence may drive future reimbursement and adoption, while new product launches await pricing clarity.Based on Castle Biosciences, Inc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.